Vitamin D supplementation during pregnancy inhibits the activation of fetal membrane NF-κB pathway.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Nuclear Factor-κB (NF-κB) is an important member of the basic cellular inflammatory pathway that regulates inflammation and apoptosis in fetal membranes.

Vitamin D (VD) exerts its anti-inflammatory and immunomodulatory effects via the NF-κB pathway.

This study was designed to investigate amniotic fluid NF-κB levels in pregnant women undergoing VD replacement therapy.

Who Took Part

According to the abstract, 20 patients were involved.

PubMed tags the participants as women only.

Sixty patients who received antenatal vitamin D supplementation from the 14th week of pregnancy until delivery were included in the study.

Participants were selected among those whose serum vitamin D levels were compatible with insufficiency (20-30 ng/mL), according to the Endocrine Society proposal.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Participants were divided into three groups with 20 patients in each group and one of the cholecalciferol or placebo treatments was given.

Patients in group 3 were not given cholecalciferol treatment (placebo).

Patients in all groups underwent elective cesarean section.

Amniotic fluid samples were collected after the fetal membranes were cut and before the fetal parts were manually removed.

What Was Measured

PubMed files the paper under topics including Amniotic Fluid, Cesarean Section, Cholecalciferol, Dietary Supplements, Extraembryonic Membranes, NF-kappa B and Vitamin D.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 20 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (European review for medical and pharmacological sciences), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.